NZ502480A - Pharmaceutical peptide formulations for treatment of dust mite allergy - Google Patents

Pharmaceutical peptide formulations for treatment of dust mite allergy

Info

Publication number
NZ502480A
NZ502480A NZ502480A NZ50248098A NZ502480A NZ 502480 A NZ502480 A NZ 502480A NZ 502480 A NZ502480 A NZ 502480A NZ 50248098 A NZ50248098 A NZ 50248098A NZ 502480 A NZ502480 A NZ 502480A
Authority
NZ
New Zealand
Prior art keywords
seq
peptide
peptides
dpi
dpii
Prior art date
Application number
NZ502480A
Inventor
Xian Chen
Sean Evans
Ze Ev Shaked
Henry M Franzen
Mei-Chang Kuo
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of NZ502480A publication Critical patent/NZ502480A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A47FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47CCHAIRS; SOFAS; BEDS
    • A47C7/00Parts, details, or accessories of chairs or stools
    • A47C7/36Support for the head or the back
    • A47C7/38Support for the head or the back for the head
    • A47C7/383Detachable or loose head- or neck-supports, e.g. horse-shoe shaped
    • AHUMAN NECESSITIES
    • A47FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47CCHAIRS; SOFAS; BEDS
    • A47C16/00Stand-alone rests or supports for feet, legs, arms, back or head
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S297/00Chairs and seats
    • Y10S297/03Pneumatic

Abstract

Disclosed are in vitro methods of treating sensitivity to house dust mite allergens comprising administering simultaneously or sequentially at least two different compositions that consist of multipeptide formulations of peptides and modified peptides of Group I and Group II Der p and Der f derived protein allergens that have been optimised for stability, efficacy and dosage. (62) Divided out of 331232

Description

<div class="application article clearfix" id="description"> <p class="printTableText" lang="en">502480 <br><br> PATENTS FORM 5 PATENTS AGT 1953 COMPLETE SPECIFICATION <br><br> Number Dated <br><br> Divided out of application no. 331232 filed 12 April 1995 <br><br> PHARMACEUTICAL PEPTIDE FORMULATIONS FOR TREATMENT OF DUST MITE ALLERGY <br><br> We, IMMULOGIC PHARMACEUTICAL CORPORATION, a US company of 610 Lincoln Street, Waltham, MA 02154, United States of America, do hereby declare the invention for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement. <br><br> - 1 - <br><br> (followed by la) <br><br> 159473 vl WGN * <br><br> Pharmaceutical Peptide Formulations for Treatment of Dust Mite Allergy <br><br> Background of the Invention 5 Approximately 500 million people around the world are allergic to dust mites and it is believed that allergy to dust mites may be a factor in 50% to 80% of patients with asthma as well as a numerous cases of eczema, hay fever, and other allergic symptoms. Dust mites are ubiquitous in homes, and thrive in beds, draperies and carpets. It is extremely difficult to remove them from the living environment and an 10 allergic individual is constantly exposed to the allergen and such constant exposure may cause the allergic condition to worsen with time. Thus, allergy to dust mite may be chronic and difficult to treat. <br><br> Allergy to mites of the genus Dermatophagoid.es has ...een associated with a number of allergic conditions such as asthma, rhinitis, and ectopic dermatitis. Two 15 species, D. pteronyssinus and D. farinae predominate and as a result, considerable effort has been expended in trying to identify allergens produced by these two species. Researchers have documented the importance of responses to the Group I (e.g. Der p I, and Der f I) and Group II (e.g. Der p II and Der f IT) protein allergens. For example, it has been documented that over 60% of patients have at least 50% of their anti-mite 20 antibodies directed toward these proteins(e.g., Lind, P. et al., Allergy. 39:259-274 <br><br> (1984); van der Zee, J.S. et al., Journal Allergy and Clinical Immunology. 81:884-896 (1988)). It is possible that children show a greater degree of reactivity to the Group I and GrcJup II allergens (Thompson, P.J., et al., Immunology. 64:301-314 (1988)). <br><br> A concerted effort has been made to characterize by gene cloning the 25 major allergens from both D. pteronyssinus and D. farinae. Consequently, <br><br> several publications have reported the complete nucleotide sequences of several allergens including Der p I (Thomas, W.R., et al., International Archives of Allergy and Applied Immunology. 85:127-129 (1988); and Chua, K.Y., et al., <br><br> Journal of Experimental Medicine. 167:175-182 (1988)), Derp II (Chua, K.Y., 30 et al.. International Archives of Allergy and Applied Immunology. 91:118-123 (1990)), Derf I (Dilworth, R.J., et al., Clinical and Experimental Allergy. 21:25-32 (1891)), Derf II (Yuuki, T., et al., Japan Journal Allergol.. 39:557-461 <br><br> (1990); and Trudinger, M., et al., Clinical and Experimental Allergy. 21:33-37 <br><br> (1991)) and a low molecular weight allergen (Ovey, E.R., et al., Journal of 35 Experimental Medicine. 170:1457-1462 (1989)). <br><br> The published nucleotide sequences of cDNAs encoding Der p I and Der fl demonstrate that these two proteins are highly homologous at the amino acid <br><br> level (81% identity) and that the mature protein products are comprised of 222 and 223 residues, respectively (Chua, K.Y., et al., Journal of Experimental Medicine. 167:175-182 (1988); and Dilworth, R.J., et al., supra)). The protein allergens Derp II and Derf II are both comprised of 129 residues, and are also 5 highly homologous (88% identity) in amino acid sequence (Trudinger, M., et al. <br><br> supra: Yuuki, T., et al. supra"): Chua, K.Y., et al. International Archives of Allergy and Applied Immunology. 91:118-123 (1990'n. <br><br> The isolation of cDNAs clones encoding Der p I and Der p II has permitted antibody binding studies on the recombinant antigens (Green, W.K., 10 et al.. International Archives of Allergy and Applied Immunology. 92:30-38 (1990); Chua, K.Y., et al., International Archives of Allergy and Applied Immunology. 21:124-129 (1990)). Complementary DNA fragments of Der p I have been expressed in E. coli and IgE binding studies with pooled human mite allergic IgE sera have demonstrated binding and non-binding regions , <br><br> 15 throughout the molecule ("Thomas. W.R.. et al.. In: Epitopes of Atopic <br><br> Allergens. Proceedings of Workshop from XIV Congress of the European Academy of Allergy and Clinical Immunology. Berlin, Sept. 1989. pp 77-82). <br><br> T cell epitopes of Der p I have been reported (O'Hehir, R.E., et al., Annual Review Immunology. 9:67-95 (1991); Stewart, G.A., et al., In: Epitopes of 20 Atopic Allergens. Proceedings of Workshop from XIV Congress of the <br><br> European Academy of Allergy and Clinical Immunology. Berlin. Sept. 1989. <br><br> pp 41-47; Yessel, H., et al., In: T cell Activation in Health and Disease: <br><br> Discrimination Between Immunity and Tolerance, Conference 22-26 Sept., 1990, Trinity College, Oxford, U.K. and Hessel, H., et al., Journal of 25 Immunology. 148(3): 738-745 (Feb. 1, 1992). <br><br> Presently, desensitization therapy is used for the treatment of house dust mite allergy. Such therapy includes administration of an extract derived from whole house dust mite cultures to an allergic individual. Desensitization therapy using such extract has drawbacks in that it can elicit anaphylaxis if high 30 doses are used, whereas when low doses are used to avoid anaphylaxis, <br><br> treatment is not highly effective and must be continued for several years to build up tolerance to the extract. <br><br> W093/08279 and W094/24281 disclose improved compositions and methods for treatment of allergy to house dust mite which greatly minimizes the potential 35 adverse effects associated with conventional desensitization therapy using whole house dust mite extract. W093/08279 and W094/24281 disclose isolated antigenic fragments or peptide derived from Der p I, Der p II, Derf I and Derf 11 which when <br><br> administered to a dust mite sensitive individual, are capable of down regulating the allergic response of the individual to house dust mite. Such down regulation of the allergic response of the individual results in diminution or alleviation of the classic symptoms of allergy including asthmatic symptoms induced by house dust mite. Such 5 antigenic fragments are disclosed in W093/08279 and W094/24281 as being capable of eliciting a T cell response such as stimulation (i.e. T cell proliferation or lymphokine secretion) and/or are capable of inducing T cell nonresponsiveness or reduced T cell responsiveness when challenged with a house dust mite allergen. In addition, W093/08279 and W094/24281 disclose that the most preferred peptides 10 derived from Der p and Derf Group I and Group II protein allergens suitable for therapeutic use do not bind IgE specific for such Der p and Derf proteins, or bind IgE to a .substantially lesser extent than the native dust mite protein allergen, thereby reducing or eliminating the possibility of anaphylaxis in a treatment regimen which includes such peptides. Furthermore, W093/08279 and W094/24281 disclose'*that 15 given the cross reactivity within the interspecies Group I allergens (i.e., Der p I and Derf I) and the interspecies Group II allergens (i.e., Der p II and Der/II), peptides of Group I, for example, derived from one species (e.g., Der p I) are capable of eliciting a T cell response from T cells specific for the other species (e.g., Derf I), and vice-versa. Finally, W093/08279 and W094/24281 disclose peptides which possess the 20 characteristics described above. <br><br> As a result of extension preformulation efforts, the applicant has provided methods for treating sensitivity to house dust allergens in humans and other mammals using novel compositions and multipeptide formulations of peptides derived from Der p and Derf Group I and Group II protein allergens which are optimal for preparation of a drug product suitable for use in treating house dust mite allergy in humans and other <br><br> 25 mammals. Such novel compositions and multipeptide formulations of Der p and Derf protein allergen peptides for use as an optimized human drug product have not previously been disclosed or contemplated. <br><br> Summary of the Invention <br><br> 30 The present invention and those of NZ 331232 and NZ 284637 relates to novel therapeutic compositions and multipeptide formulations of peptides and modified peptides of Group I and Group II Derp and Der f derived protein allergens. Such novel therapeutic compositions and multipeptide formulations are the result of a preformulation scheme to develop an optimized drug product for therapeutic treatment of humans suffering from allergy to' <br><br> 35 house dust mite allergens. The Der p and Der f peptides and modified peptides in acordance with the invention possess certain unique characteristics which render them particularly suitable for drug product formulation. Therapeutic compositions and <br><br> INTELLECTUAL PROPERTY OFFICE OF N.Z. <br><br> 2 4 DEC 2004 <br><br> multipeptide formulations of these inventions have been optimized to accommodate and maintain the unique characteristics of the peptides and modified peptides derived from house dust mite protein allergens and at the same time provide maximum therapeutic effect when used in therapeutic regimens for the treatment of house dust mite allergy in humans. The inventions further provide novel modified peptides derived from Derp I <br><br> and Der p II protein allergens. The peptides and formulations are covered in the parent application, NZ 284637. This divisional application relates particularly to methods for treating sensitivity to house dust mite allergen using the above formulations. Specifically the invention of this divisional application provides an in vitro method of treating sensitivity to house dust mite allergen comprising administering simultaneously or sequentially at least two different compositions comprising at least one isolated peptide selected from the group consisting of: DPI-il.2 (SEQ. ID. NO. 27) and DFI-22.2 (SEQ. ID. <br><br> NO. 28), and at least one peptide selected from the group consisting of: DPI-23.3 f (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPH-20.9 (SEQ. ID. NO. 31), DPII- <br><br> 22.14 (SEQ. ID. NO. 32) and DPd-25.15 (SEQ. ID. NO. 33) all as shown in Rg. 1. <br><br> Description of the Drawings'" <br><br> Fig. 1 shows the amino acid sequences of the "unique" peptides in accordance with the invention including the novel "unique" peptides of the invention. <br><br> &lt; <br><br> « <br><br> Fig. 2 shows overlapping peptides derived Derp I and Derp H protein allergens used in T cell studies described herein. <br><br> Fig. 3 is a graphic representation depicting T cell responses to the overlapping Der p I peptides shown in Fig. 2 and the Group I "unique" peptides, DPI-21.2 (SEQ. ID. NO. <br><br> 27), DH-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ed. . NO. 30), shown in Fig. 1. The mean S.I. shown above each bar (in parenthesis) as well as the percentage of responses, the positivity index (mean S.I. multiplied by percentage of responses), is the Y axis. <br><br> Fig. 4 is a graphic representation depicting T cell responses to the overlapping Derp II peptides, DPD-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32), and DPII- <br><br> 25.15 (SEQ. ID. NO. 33), shown in Fig. 2 and the Der p II "unique" peptides shown in Fig. 2. The mean S.I. shown above each bar (in parenthesis) as well as the percentage of responses, the positivity index (mean S.I. multiplied by percentage of responses), is the Y axis. <br><br> H <br><br> INTELLECTUAL property office of HI. <br><br> 2 4 DEC 2004 <br><br> Fig. 5 is a pH-solubility profile of "unique" candidate peptides DPI-21.2 (SEQ. ID. NO. 27), DH-22.2 (SEQ. ED. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPH-20.9 (SEQ. ID. NO. 31), DPD-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33), in 50mM sodium phosphate buffers with 5% mannitol. Solubility is measured in mg/ml (y axis) over a pH range of pH 5.5 to pH 8.5 at about 22°C ± 2. <br><br> Fig. 6 is a pH-stability profile of candidate peptides DPI-21.2 (SEQ. ID. NO. 27), DH-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), <br><br> INTELLECTUAL PROPERTY office of n.z. <br><br> 4a <br><br> 2 * DEC W ifCeiVED <br><br> DPn-20.9 (SEQ. ID. NO. 31), DPII-22.14.(SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) in an equal concentration combination. Degradation of peptide is calculated as % degradation (determined by peak area using HPLC analysis) of peptide observed after 24 hours at about 22°C + 2 and about 5°C, at various theoretical 5 concentrations of 3.0, 2.0 and .1.0 mg/ml of peptide over a pH range of 6.0 to 8.5. <br><br> Detailed Description of the Invention <br><br> The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. The PCT publications and other 10 publications cited herein are hereby, incorporated by reference. <br><br> The present invention relates to novel modified Der p I and Der p II peptides which are in combination with other Der p I and Derf I peptides are a part of a preformulation scheme to develop an optimized drug product for therapeutic treatment of humans suffering from allergy to house dust mite allergen. Such peptides and -15 modified peptides possess certain unique characteristics which render them particularly suitable for drug product formulation, and may be referred to herein as "unique" <br><br> peptides. . ' . <br><br> In accordance with pharmaceutical chemistry, preformulation is the process of optimizing a drug through determination and/or definition of those physical and 20 chemical properties considered important in the formulation of a stable, effective, and safe dosage form. The possible interactions with the various components intended for use in the final drug product are also considered. Preformulation is an intensive effort that includes the study of such parameters as solubility, pH profile of stability, and drug-excipient interactions, which may have a profound effect on a drug's 25 physiological availability and physical and chemical stability. The data obtained from such studies are integrated with those obtained from preliminary pharmacological and biochemical studies of the active drug component thus providing information that permits the selection of the best drug form, and the most desirable excipients for use in its development. <br><br> 30 The development of an optimum formulation of active drug component and excipients is complex and many factors influence formulation properties. The high degree of uniformity, the physiological availability and the therapeutic quality expected of pharmaceuticals can only be achieved by considerable effort and expertise. Flexibility is also an important factor in preformulation. Numerous excipients, 35 stabilizers counter ions and the like may have to be tested in order to find those compatible with the active drug component of the formulation. Multiple modifications of the active component may become necessary to successfully formulate a drug <br><br> £~ <br><br> product. Such modifications must not effect the overall therapeutic effectiveness of the drug but at the same time, must render the drug more suitable for formulation. <br><br> As a part of a preformulation scheme to provide an optimized drug product suitable for use in humans and other mammals for treating sensitivity to house dust 5 mite, it was determined that the active component (referred to herein as a "peptide" or "candidate peptide" or "unique peptide") in such formulation should possess the following characteristics which would render such peptides "unique" among all of the possible peptides derived from the Der p I, Der p II and Derf I protein allergen sequences. First, a unique peptide should alone or in combination with other unique 10 peptides comprise a sufficient percentage of the T cell reactivity of the Der p and Derf protein allergens to induce T cell nonresponsiveness or reduced T cell responsiveness in a substantial percentage of the individuals sensitive to house dust mite allergen. Second, the candidate peptide should possess the characteristic of "superior solubility" which is defined herein as solubility of greater than 3 mg/ml at a pH in a pH range of 15 pH 6 to pH 8 in an aqueous buffer. Third, the peptide is stable in an aqueous buffer at a pH in a pH range from pH 6 to pH 8. Candidate peptides derived from Der p and Der f protein allergens which have been determined to be "unique" peptides of the invention are DPI-21.2 (SEQ. ID. NO. 27), DH-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPH-20.9 (SEQ. ID. NO. 31), DPII-20 22.14 (SEQ. ID. NO. 32) and DPE-25.15 (SEQ. ID. NO. 33) all as shown in Fig. 1. ' In accordance with the first characteristic, Those peptides found to elicit a T cell response such as T cell proliferation or lymphokine secretion (i.e. comprise at least one T cell epitope), or induce T cell non-responsiveness or reduced T cell responsiveness are understood to have T cell reactivity. T cell epitopes are believed to 25 be involved in initiation and perpetuation of the immune response to a protein allergen which is responsible for the clinical symptoms of allergy. These T cell epitopes are thought to trigger early events at the level of the T helper cell by binding to an appropriate HLA molecule on the surface of an antigen presenting cell and stimulating the relevant T cell subpopulation. These events lead to T cell proliferation, 30 lymphokine secretion, local inflammatory reactions, recruitment of additional immune cells to the site, and activation of the B cell cascade leading to production of antibodies. One isotype of these antibodies, IgE, is fundamentally important to the development of allergic symptoms and its production is influenced early in the cascade of events, at the level of the T helper cell, by the nature of the lymphokines secreted. 35 AT cell epitope is the basic element or smallest unit of recognition by a T cell receptor, where the epitope comprises amino acids essential to receptor recognition. It is believed that exposure of house dust mite allergic patients to isolated house dust <br><br> 6 <br><br> mite Group I and Group II protein allergen peptides which comprise at least one T cell epitope may cause T cell non-responsiveness of appropriate T cell subpopulations such that they become unresponsive or have reduced responsiveness to the protein allergen and do not participate in stimulating an immune response upon such exposure for 5 example, via anergy, tolerance, or apoptosis, the ability to modify the lymphokine secretion profile as compared with exposure to the naturally occurring autoantigen; and /or the ability to cause induction of T suppresser cells. <br><br> To determine peptides having T cell reactivity and comprising at least one T cell epitope, isolated peptides are tested by, for example, T cell biology techniques, to 10 determine whether the peptides elicit a T cell response or induce T cell non- <br><br> responsiveness. As discussed in the Examples human T cell stimulating activity can be tested by culturing T cells obtained from an individual sensitive to house dust mite allergen, (i.e., an individual who has an IgE mediated immune response to house dust mite allergen) with a peptide or modified peptide derived from a Der p or DerfJSroup 15 I or Group n protein allergen and determining whether proliferation of T cells occurs in response to the peptide as measured, e.g., by cellular uptake of tritiated thymidine. Stimulation indices for responses by T cells to peptides can be calculated as the maximum counts per minute (CPM) in response to a peptide divided by the control CPM. A stimulation index (S.I.) equal to or greater than two times the background 20 level is considered "positive". Positive results are used to calculate the mean stimulation index for each peptide for the group of patients tested. Peptides suitable as candidates for formulation into a final drug product have a mean T cell stimulation index of greater than or equal to 2.0 and preferably higher, (e.g. at least 2.5, more preferably at least 3.5, more preferably at least 4.0, more preferably at least 5, even 25 more preferably at least 7 and most preferably at least about 9). <br><br> For therapeutic purposes, candidate peptides are recognized by at least 10%, more preferably at least 20%, more preferably at least 30% and even more preferably at least 40% or more of individuals in a population of individuals sensitive to house dust mite allergen. In addition, preferred candidate peptides have a positivity index 30 (P.I.) of at least about 100, more preferably at least about 250 and most preferably at least about 350. The positivity index for a peptide is determined by multiplying the mean T cell stimulation index by the percent of individuals, in a population of individuals sensitive to house dust mite allergen (e.g., preferably at least 15 individuals, more preferably at least 30 individuals or more), who have a T cell 35 stimulation index to such peptide of at least 2.0. Thus, the positivity index represents both the strength of a T cell response to a peptide (S.I.) and the frequency of a T cell <br><br> 7 <br><br> response to a peptide in a population of individuals sensitive to house dust mite allergen. <br><br> To determine whether a peptide (candidate peptide) or a combination of candidate peptides are likely to comprise a sufficient percentage of the T cell reactivity 5 of house dust mite protein allergens, to induce T cell nonresponsiveness in a substantial percentage of a population of individuals sensitive to house dust mite allergen, an algorithm can be used. In accordance with one such algorithm, a set of overlapping peptides is produced by systematically dividing the protein allergen(s) of interest into at least two overlapping peptide regions of desired lengths (e.g., of about 10 12-30 amino acid residues in length, preferably not longer than about 25 amino acid residues in length with about 5-15 amino acid residues of overlap). This division into peptide regions can be arbitrary, can be made according to an algorithm, or can be wholly or partially based on regions of house dust mite Group I and/or Group II protein allergens known to comprise at least one T cell epitope. Preferably, at least 15 50% of the entire house dust mite protein allergen sequence and more preferably, the entire house dust mite protein allergen sequence is divided into two or more peptides. A human T cell stimulation index is determined for each of the peptides in an in vitro T cell proliferation assay as described herein for each individual tested in a population of individuals sensitive to the protein antigen. For example both W093/08279 and 20 W094/24281 disclose T cell studies with overlapping peptides derived from Der p I, -Der p II, Derf I and DerfTL. A candidate peptide or combination of candidate peptides is selected based, at least in part, on the mean human T cell stimulation index of the candidate peptide in the set of peptides tested and the positivity index of the candidate peptide in the set of peptides tested (see, Figs. 3 and 4). The human T cell 25 stimulation index for the candidate peptide(s) is summed. For each individual, the human T cell stimulation index for the candidate peptide(s) is divided by the sum of the human T cells stimulation indices of the remaining peptides in the set of peptides tested to determine a percent of T cell reactivity as shown below: <br><br> 30 Candidate S.I. <br><br> (1) % T Cell Reactivity of a candidate peptide(s) = X 100 <br><br> Sum of S.I. of the set of Overlapping peptides <br><br> 35 Alternatively, the presence of T cell epitopes in the candidate peptide dependent on amino acids residues in an overlapping peptide located at either the N-terrninus or C-terminus of the candidate peptide in the amino acid sequence of the protein antigen, but which epitopes are not present in the candidate peptide can be <br><br> ? <br><br> considered in calculating the percent of T cell reactivity in the candidate peptide by use of the following formula: <br><br> (2) % T Cell Reactivity of a candidate peptide(s) = <br><br> Nj flanking peptide S.I. + Candidate peptide S.I. + C-p flanking peptide S.I <br><br> Sum of S.I. of the set of overlapping peptides x 100 <br><br> 10 In this formula, "Nj flanking peptide" refers to a peptide which comprises amino acid residues which overlap with amino acid residues located at the N-terminus of the candidate peptide in the amino acid sequence of the protein antigen from which the peptide is derived; "Cj flanking peptide" refers to a peptide which comprises amino acid residues which overlap with amino acid residues located a the C-terminus 15 of the candidate peptide in the amino acid sequence of the protein antigen from which the peptide is derived. In this calculation stimulation indices for the candidate peptide, the N-terminal flanking peptide and the C-terminal flanking peptide are added and divided by the sum total of the stimulation indices for the entire set of overlapping peptides obtain a percent of T cell reactivity for the candidate peptide. If a 20 combination of two or more candidate peptides is selected each of which contains amino acid residues which overlap, this calculation cannot be used to determine a percent of T cell reactivity for each candidate peptide separately. However, a total percent of T cell reactivity for the combination of candidate peptides can be obtained. In this situation, the stimulation indices for all of the candidate peptides which overlap 25 is included in the calculation. <br><br> The values obtained for the percentage of T cell reactivity for the candidate peptide or combination of peptides in each individual tested can be expressed as a range of the lower and higher values of the results of the above described calculations. By either of the above calculations, the percent is obtained for at least about twenty 30 (20) and preferably at least about thirty (30) individuals sensitive to the protein antigen and a mean percent is determined. For use in the compositions of the invention, the candidate peptide or combination of candidate peptides has the following criteria: (1) the candidate peptide or combination of candidate peptides has a mean percent of at least about 10%, preferabl; at least about 20%, more preferably at least about 30%, 35 more preferably at least about 40% and more preferably at least about 50-60% or greater; and (2) in the population of individuals tested at least about 60%, preferably at least about 75%, and more preferably at least about 90-100% have positive T call responses (S.I. equal to or greater than 2.0) in response to the candidate peptide or combination of candidate peptides. A candidate peptide or combination of candidate <br><br> peptides meeting the above criteria is likely to comprise a sufficient percentage of the T cell reactivity to house dust mite protein allergen to induce T cell non-responsiveness or reduced T cell responsiveness in a substantial percentage of a population of individuals sensitive to house dust mite. <br><br> 5 As an illustrative embodiment of the above-described algorithm, a set of overlapping peptides and candidate peptides derived from Der p I and Der p II respectfully were produced and tested. Secondary T cell cultures determined to be reactive with Der p I protein allergen were derived from 39 house dust mite-allergic subjects and analyzed for reactivity to an overlapping set of peptides, as well as 10 candidate peptides derived from Der p I and Der f I protein allergen, DPI-21.2 (SEQ. ID. NO. 27), DH-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29) and DPI-26.6 (SEQ. ID. NO. 30), in an in vitro T cell proliferation assay as described herein. The results are shown in Fig. 3. The highest stimulation index greater than or equal to 2.0 in response to each peptide was recorded for each subject tested. The data were then 15 analyzed by the equations above. The results and calculations of the percent of T cell reactivity for a single dust mite-allergic subject are shown below using formulas (1) and (2). <br><br> 20 <br><br> T CELL REACTIVITY FOR PATIENT 1733 PEPTIDE STIMULATION INDEX <br><br> DPI-21.2 (SEQ. ID. NO. 27) <br><br> 3.6 <br><br> DPI-3 (SEQ. ID. NO. 3) <br><br> 3.9 <br><br> DPI-22.2 (SEQ. ID. NO. 28) <br><br> 3.1 <br><br> DPI-12.1 (SEQ. ID. NO. 6) <br><br> 2.2 <br><br> DPI-5.1 (SEQ. ID. NO. 7) <br><br> 3.5 <br><br> DPI-23.31 (SEQ. ID. NO. 29) <br><br> 5.7 <br><br> DPI-14 (SEQ. ID. NO. 9) <br><br> 2.3 <br><br> DPI-15 (SEQ. ID. NO. 10) <br><br> 2.8 <br><br> DPI-6.1 (SEQ. ID. NO. 11) <br><br> 2.1 <br><br> DPI-7.1 (SEQ. ID. NO. 12) <br><br> 2.2 <br><br> DPI-26.6 (SEQ. ED. NO. 30) <br><br> 5.0 <br><br> DPI-9 (SEQ. ID. NO. 14) <br><br> 2.4 <br><br> DPI-16 (SEQ. ID. NO. 15) <br><br> 2.0 <br><br> DPI-10 (SEQ. ID. NO. 16) <br><br> 0 <br><br> DPI-17 (SEQ. ID. NO. 17) <br><br> 0 <br><br> SUM OF STIMULATION INDICES 40.8 (DENOMINATOR) <br><br> 10 <br><br> % Reactivity of Peptide DPI-26.6 (SEQ. ID. NO. 30) for patient 1733 is (1) DPI-26.6 (S.I.) 5.0 <br><br> X 100 = 12.3% <br><br> 40.8 40.8 <br><br> 10 (2) DPI-7.1 +DPI-26.6+DPI-9 2.2+5.0+2.4 <br><br> = X 100 = <br><br> 24% <br><br> 40.8 40.8 <br><br> 15 <br><br> Therefore the estimated range of T cell reactivity for Peptide DPI-26.6 (SEQ. ID. NO. 30) for this patient is 12.3%-24% of the total reactivity of the Der p I protein. The above calculation is repeated for any potential candidate peptides for each patient tested. In the population of 39 Cry j I-allergic subjects tested the following results 20 were obtained: <br><br> Candidate <br><br> Range of mean percentage <br><br> Frequency of response <br><br> Peptides <br><br> T Cell Reactivitv at least one peptide <br><br> DPI-21.2 <br><br> 25 <br><br> (SEQ. ID. NO. 27), DH-22.2 <br><br> (SEQ. ID. NO. 28) <br><br> DPI-23.31 <br><br> (SEQ. ID. NO. 29), <br><br> 30 <br><br> DPI-26.6 <br><br> (SEQ. ID. NO. 30) <br><br> 38-67% <br><br> 82% <br><br> Thus, the combination of the four candidate peptides are well within the desired range for possessing, in combination, sufficient T cell reactivity of Group I protein allergen 35 of Derf and Der p, and meet the first characteristic of a "unique" peptide of the invention. <br><br> The same calculation were determined for the Group II, Der p protein allergen. Secondary T cell cultures determined to be reactive with Der p I protein allergen were derived from 30 house dust mite-allergic subjects and analyzed for reactivity to an 40 overlapping set of peptides, as well as candidate peptides derived from Der p II, DPII-20.9 (SEQ. ID. NO: 31), DPII-22.14 (SEQ. ID. NO. 32)and DPII-25.15 (SEQ. ED. NO. 33), in an in vitro T cell proliferation assay as described herein. The results are shown in Fig.4. The highest stimulation index greater than or equal to 2.0 in response to each peptide was recorded for each subject tested. The data were then analyzed by the <br><br> U <br><br> equations above. In the population of 30 house dust mite-allergic subjects tested the following results were obtained: <br><br> Candidate Range of mean percentage Frequency of response <br><br> 5 Peptides T Cell Reactivity at least one peptide <br><br> DPII-20.9 (SEQ. ID. NO. 31), <br><br> DPII-22.14 (SEQ. ID. NO. 32) <br><br> 10 DPII-25.15 <br><br> (SEQ. ED. NO. 33) 37-51% 63% <br><br> Thus, the combination of the three Der p II candidate peptides of the invention are well within the desired range for possessing, in combination, sufficient T cell reactivity of 15 Group II house dust mite protein allergen of Der p, and meet the first characteristic of a "unique" peptide of the invention. ' <br><br> For the treatment of allergy in accordance with the methods of the invention, it is preferred that a peptide used in conjunction therewith does not bind immunoglobulin E (IgE) or binds IgE to a substantially lesser extent (i.e. at least 100-fold less binding 20 and more preferably, at least 1,000-fold less binding) than the respective house dust mite protein allergen from which the peptide is derived binds IgE. The major complications of standard immunotherapy are IgE-mediated responses such as anaphylaxis. Immunoglobulin E is a mediator of anaphylactic reactions which result from the binding and cross-linking of antigen to IgE on mast cells or basophils and the 25 release cff mediators (e.g., histamine, serotonin, eosinophil chemotacic factors) in allergic ("atopic") patients. Thus, anaphylaxis in a substantial percentage of a population of individuals sensitive to the allergen being treated could be avoided by the use in immunotherapy of a peptide or peptides which do not bind IgE in a substantial percentage (e.g., at least about 75%) of a population of individuals sensitive 30 to house dust mite allergen, or if the peptide binds IgE, such binding does not result in the release of mediators from mast cells or basophils. The risk of anaphylaxis could be reduced by the use in immunotherapy of a peptide or peptides which have reduced IgE binding. IgE binding may be tested, for example by direct ELISA or capture ELIS A. Moreover, peptides which have minimal IgE stimulating activity are desirable for 35 therapeutic effectiveness. Minimal IgE stimulating activity refers to IgE production that is less than the amount of IgE production and/or EL-4 production stimulated by the native respective house dust mite protein allergen. If a peptide binds IgE, it is preferable that such binding does not result in the release of mediators (e.g. histamines) from mast cells or basophils. To determine whether a peptide that binds IgE causes <br><br> } oL <br><br> the release of mediators, a histamine release assay can be performed using standard reagents and protocols obtained for example, from Amac, Inc. (Westbrook, ME). <br><br> Briefly, a buffered solution of a peptide to be tested is combined with an equal volume of whole heparinized blood from an allergic subject. After mixing and incubation, the 5 cells are pelleted and the supematants are processed and analyzed using a radio immunoassay to determine the amount of histamine released. Experiments to date indicate that candidate peptides DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ID. NO. 31), DPH-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) exhibit 10 negative IgE reactivity or histamine release (data not shown). <br><br> The second characteristic for a unique peptide is that of "superior solubility" <br><br> which was defined earlier as being solubility of greater than 3 mg/ml at a pH in a range of pH 6 to pH 8. Solubility in a physiologically acceptable pH range (e.g. pH 6 to pH 8) is particularly important when formulating a multipeptide therapeutic for injection. 15 Administration of a soluble drug product in a physiologically acceptable pH range by intravenous or subcutaneous injection provides about 100% bioavailability of the drug component to the physiological system into which the drug is being introduced. Thus, <br><br> it is necessary that a drug product intended for injection be fluid to the extent that easy syringability exists, and the active component be soluble as well if maximum 20 therapeutic effect is to be achieved. Solubility is also useful when formulating compositions to be administered via other modes of administration such as by oral administration (tablet, aerosol, sublingual), or sustained release preparations and formulations. <br><br> Proteins and peptides may be difficult to formulate into soluble compositions 25 as a peptide may not be soluble in any desirable pH range or may be soluble in only a narrow pH range. It is particularly difficult when multiple peptides are being formulated together into a single multipeptide formulation, as each peptide may be soluble in a pH range which does not overlap with those of the other peptides in the formulation. As a result, it is the requirement of "superior solubility" which requires 30 the most formulation flexibility in that considerable modification of the targeted candidate peptides may be necessary to successfully formulate a multipeptide drug product. <br><br> Some of the unique peptides used in the invention are the product of multiple amino acid modifications of the original targeted candidate peptide sequence ("parent") from 35 which the modified unique peptides of the invention were originally derived. Such modified "unique" peptides of the invention include DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ED. <br><br> 13 1 INTELLECTUAL PROPERTY OFFICE <br><br> OF N.Z. <br><br> 2 k DEC 2004 # <br><br> RECEIVED <br><br> NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) all as shown in Fig. 1. For example, the amino acid sequence of DpII-22.14 (SEQ. ID. NO. 32) was derived from the protein sequence of Der p II by first identifying those regions of the native protein with high T-cell reactivity using a set of overlapping peptides that covered the entire protein 5 sequence. Several peptides were found to exhibit high T-cell reactivity, corresponding to three different locations/areas in the protein. One of these areas were covered by three adjacent peptides each being about 25-29 amino acids long and with 10-15 amino acids overlap, DpD-3.1 (SEQ. ID. NO. 20), DpII-4 (SEQ. ID. NO. 21)and DpH-5 (SEQ. ID. NO. 22) (Fig. 2) that all exhibited high T-cell reactivity. Based on this T-cell 10 map a new peptide was synthesized, with the amino acid sequence <br><br> QLEAVFEANQNTKTAKEEIKASIDGLEV (SEQ. ID. NO. 34), 28 amino acids long, which exhibits most of the reactivity found in the individual peptides (data not shown) and contains all of DpII-4 (SEQ. ID. NO. 21)and parts of DpII-3.1 (SEQ. ID. NO. 20) and DpII-5 (SEQ. ID. NO. 22). However, this peptide did not meet the "superior 15 solubility" requirement of 3 mg/ml for a "unique peptide of the invention nor did it meet the stability requirement. Therefore two analogs were made with addition of one or two charged residues at each end, DpII-22.2 <br><br> KQLEAVFEANQNTKTAKIEIKASIDGLEVK (SEQ. ED. NO. 35) and DpH-22.6 DKQLEAVFEANQNTKTAKEEIKASEDGLEVD (SEQ. ED. NO. 36) and the stability 20 improved substantially but the solubility did not reach the standard of a "superior solubility". In the second attempt a series of truncated analogs with up to five charged amino acid residues added to the ends (Table 1). <br><br> 'i <br><br> Dpll-22 (SEQ. ed. NO. 34) <br><br> qleavfeanqntktakieikasidglev <br><br> Dpll-22.2 (SEQ. ID. NO. 35) <br><br> KQLEAVFEANQNTKTAKIEIKASIDGLEVK <br><br> Dpll-22.6 (SEQ. ID. NO. 36) <br><br> DKQLEAVFEANQNTKTAKIEIKASIDGLEVD <br><br> Dpll-22.4 (SEQ. ID. NO. 37) <br><br> QLEAVFEANQNTKTAKIEIKASIDE <br><br> Dpll-22.5 (SEQ. ID. NO. 38) <br><br> DKQLEAVFEANQNTKTAKIEIKASIDE <br><br> Dpll-22.8 (SEQ. ID. NO. 39) <br><br> DKQLEAVFEANQNTKTAKIEIKASIDE <br><br> DplI-22.9 (SEQ. ID. NO. 40) <br><br> DKEQLEAVFEANQNTXTAKIEIKASIDEE <br><br> Dpll-22.12 (SEQ. ID. NO. 41) <br><br> DKQLEAVFEANQA.TKTAKIEIKASIDE <br><br> Dpll-22.16 (SEQ. ID. NO. 42) <br><br> DKELEAVFEANQNTKTAKIEIKASD <br><br> Dpll-22.19 (SEQ. ID. NO. 43) <br><br> DKELEAVFEANQNTKTAKIEIKAD <br><br> Dpll-22.20 (SEQ. ID. NO. 44) <br><br> dkeleavfeanqntktakieikak <br><br> Dpll-22.21 (SEQ. ID. NO. 45) <br><br> DKELEAVFEANQNTKTAKIEIKD <br><br> Dpll-22.22 (SEQ. ID. NO. 46) <br><br> DKELEAVFEANQNTKTAKIEIKK <br><br> Dpll-22.26 (SEQ. ID. NO. 47) <br><br> dkeleavfeanqntktakieik <br><br> Dpll-22.23 (SEQ. ID. NO. 48) <br><br> DKELEAVFEANQNTKTAKIED <br><br> Dpll-22.24 (SEQ. ID. NO. 49) <br><br> DKELEAVFEANQNTKTAKIEK <br><br> Qpll-22.25 (SEQ. ID. NO. 50) <br><br> DKELEAVFEANQNTKTAKIE <br><br> Dpll-22.14 (SEQ. ID. NO. 32) <br><br> DKELEAVFEANQNTKTAKAE <br><br> Dpll-22.10 (SEQ. ed. NO. 51) <br><br> LEAVFEANQNTKTAK <br><br> Dpll-22.11 (SEQ. ID. NO. 52) <br><br> LEAVFEANQATKTAK <br><br> Dpll-22.18 (SEQ. ID. NO. 53) <br><br> DKTAKIEIKASIDGLE <br><br> Dpll-22.15 (SEQ. ID. NO. 54) <br><br> KTAKIEIKASIDGLE <br><br> Table 1 <br><br> Of these the DpII-22.5, DKQLEAVFEANQNTKTAKIEIKASIDE (SEQ. ID. NO. 38), 5 was promising since it retained the T-cell reactivity of the "parent" peptide, DPII-22, (SEQ. ID. NO. 34)and was very soluble, but it was very difficult to synthesize. The difficulties in synthesizing this sequence were found to disappear with the replacement of the hydrophobic isoleucine with the less hydrophobic alanine and simultaneously the solubility increased by an order of magnitude. Peptide DpII-22.14, 10 DKELEAVFEANQNTKTAKAE (SEQ. ID. NO. 32), was found to possess almost the <br><br> IS' <br><br> 9 <br><br> t same T-cell reactivity as the "parent" peptide Dpll-22 (SEQ. ID. NO. 34)as well as being soluble at greater than 3 mg/ml at a pH in the pH range 6.0 to 8.0, and was easy to synthesize and purify. Therefore, DPII-22 (SEQ. ID. NO. 34) was chosen as a "unique" peptide when it was determined to be stable at a pH in the range of 6.0 to 8.0. 5 The development of the other modified "unique" peptides, DpI-23.31 (SEQ. ID. NO. 29), DpI-26.6 (SEQ. ED. NO. 30) and DpII-25.15 (SEQ. ID. NO. 33), followed a process similar to that described above for DpII-22.14 (SEQ. ID. NO. 32). Peptides DPII-22.14 (SEQ. ED. NO. 32), DpI-23.31 (SEQ. ID. NO. 29), DpI-26.6 (SEQ. ID. NO. 30) and DpII-25.15 (SEQ. ID. NO. 33), all as shown in Fig. 1 are novel modified 10 peptides of this invention. <br><br> The third criteria which the unique peptides of this invention must meet is stability, particularly solution stability, in a physiologically acceptable pH range of pH 6 to pH 8. It must be stable under the conditions of manufacture and storage, and under conditions of reconstitution if necessary. Stability testing establishes the time 15 period for which the integrity, quality and purity of the drug product is preserved in its finished dosage form. Stability testing may be performed concurrently with solubility studies as discussed in Example 3. Ail equal concentration composition comprising each of the candidate peptides of the invention remained stable (e.g. no significant degradation) in solution at a common "window" within the pH range from pH 6-pH 8 20 at about room temperature and at about 5°C for at least 24 hours (see, Fig. 6). <br><br> Therefore, candidate peptides DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ED. NO. 28), DPI-23.31 (SEQ. ED. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ED. NO. 31), DPII-22.14 (SEQ. ED. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) possess each of the three required "unique" characteristics outlined above, indicating 25 that this combination of peptides is suitable for formulation as an optimized therapeutic drug product for administration to humans for treatment of allergy to house dust mite allergen. <br><br> Highly purified peptides for use in this invention, may be produced synthetically by chemical synthesis using standard techniques. Various methods of chemically 30 synthesizing peptides are known in the art such as solid phase synthesis which has been fully or semi automated on commercially available peptide synthesizers. Synthetically produced peptides may then be purified to homogeneity (i.e. at least 90%, more preferably at least 95% and even more preferably at least 97% purity), free from all other polypeptides and contaminants using any number of techniques known 35 in the literature for protein purification. <br><br> In accordance with one procedure for producing highly purified homogenous peptides used in the invention, a peptide produced by synthetic chemical means (either <br><br> /6 <br><br> INTELLECTUAL PROPERTY OFFICE OF N.Z. <br><br> 2 h DEC 2004 <br><br> 4 <br><br> RECEIVED <br><br> anchored to a polymer support "solid phase synthesis" or by conventional homogenous chemical reactions "solution synthesis") may be purified by preparative reverse phase chromatography. In this method, the synthetically produced peptide in "crude" form is dissolved in an appropriate solvent (typically an aqueous buffer) and applied to a 5 separation column (typically a reverse phase silica based media, in addition, polymer or carbon based media may be used). Peptide is eluted from the column by increasing the concentration of an organic component (typically acetonitrile or methanol) in an aqueous buffer (typically TFA, triethylamine phosphate, acetate or similar buffer). Fractions of the eluate will be collected and analyzed by appropriate analytical 10 methods (typically reverse phase HPLC or CZE chromatography). Those fractions having the required homogeneity will be pooled. The counter ion present may be changed by additional reverse phase chromatography in the salt of choice or by ion exchange resins. The peptide may then be isolated as its acetate or other appropriate salt. The peptide is then filtered and the water removed (typically by lyophilizatjon) to 15 give a homogenous peptide composition containing at least 90%, more preferably at least 95% and even more preferably at least 97% of the required peptide component. Optionally, or in conjunction with reverse phase HPLC as described above, <br><br> purification may be accomplished by affinity chromatography, ion exchange, size exclusion, counter current or normal phase separation systems, or any combination of 20 these methods. Peptide may additionally be concentrated using ultra filtration, rotary * evaporation, precipitation, dialysis or other similar techniques. <br><br> The highly purified homogenous peptide composition is then characterized by any of the following techniques or combinations thereof: a) mass spectroscopy to determine molecular weight to check peptide identity; b) amino acid analysis to check 25 the identity of the peptide via amino acid composition; c) amino acid sequencing <br><br> (using an automated protein sequencer or manually) to confirm the defined sequence of amino acid residues; d) HPLC (multiple systems if desired) used to check peptide identity and purity (i.e. identifies peptide impurities); e) water content to determine the water concentration of the peptide compositions; f) ion content to determine the 30 presence of salts in the peptide composition; and g) residual organics to check for the presence of residual organic reagents, starting materials, and/or organic contaminants. <br><br> A peptide for use in the invention may also be produced by recombinant DNA techniques in a host cell transformed with a nucleic acid sequence coding for such peptide. When produced by recombinant techniques, host cells transformed with 35 nucleic acid encoding the desired peptide are cultured in a medium suitable for the cells and isolated peptides can be purified from cell culture medium, host cells, or both using techniques known in the art for purifying peptides and proteins including ion- <br><br> 17 <br><br> 2 * DEC 2004 I RECeiuen <br><br> exchange chromatography, ultra filtration, electrophoresis or immunopurification with antibodies specific for the desired peptide. Peptides produced recombinantly may be isolated and purified to homogeneity, free of cellular material, other polypeptides or culture medium for use in accordance with the methods described above for 5 synthetically produced peptides. <br><br> In certain limited circumstances, peptides for use in this invention may also be produced by chemical or enzymatic cleavage of a highly purified full length or native protein of which the sites of chemical digest or enzymatic cleavage have been predetermined and the resulting digest is reproducible. Peptides having defined amino 10 acid sequences can be highly purified and isolated free of any other poly peptides or contaminants present in the enzymatic or chemical digest by any of the procedures described above for highly purified, and isolated synthetically or recombinantly produced peptides. <br><br> Disclosed herein are , therapeutic compositions and s 15 multipeptide therapeutic formulations comprising the unique peptides for use in the invention. Therapeutic compositions for use in the invention may comprise one or more of the unique peptides which may be administered simultaneously or sequentially as single treatment episode for treatment of allergy to house dust mite allergen in a human or other mammal. Such a treatment regimen may not necessarily be a physical 20 mixture of more than one peptide of the invention, but does comprise a combination of such peptides administered simultaneously or sequentially as a single treatment episode in order to achieve the maximum therapeutic effect the combination of the unique peptides, DPI-21.2 (SEQ. ID. NO. 27), DH-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ID. NO. 31), DPII-25 22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) provide (e.g. solubility and stability in acceptable physiological pH range as well as having a range of T cell reactivity of 38-67% of the total T cell reactivity of the Group I house dust mite protein allergen and a frequency of response of 91% for at least one Der p I peptide tested in a population of individuals allergic to house dust mite and similarly, have a 30 range of T cell reactivity of 37-51 % of the total T cell reactivity of the Group II house dust mite protein allergen and a frequency of response of 63% for at least one Der p II peptide tested in a population of individuals allergic to house dust mite). <br><br> Therapeutic compositions used in the invention may comprise one or more of peptides DPI-21.2 (SEQ. ID. NO. 27), DH-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 35 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. <br><br> ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) also comprise one or more pharmaceutically acceptable carriers such as excipients which are compatible with ft <br><br> INTELLECTUAL PROPERTY office of N.Z. <br><br> 2 &lt;i DEC 2004 RECEIVED <br><br> peptide or peptides present in a single composition. When the composition is a multipeptide formulation, the pharmaceutically acceptable carrier must be compatible with all of the peptides in the multipeptide formulation. Preferred excipients include but are not limited to sterile water, sodium phosphate, mannitol, or both sodium 5 phosphate and mannitol or any combination thereof. Other suitable excipients include but are not limited to sorbitol, sucrose, dextrose, lactose dextran and PVP. <br><br> Additionally, due to the potential for dimerization of the peptides in a mutlipeptide formulation, there may also be included an agent such as EDTA to prevent dimerization. Alternatively, any other material or procedures known in the art to 10 prevent dimerization may be used. In addition, pharmaceutically acceptable counter ions may be added during the preparation of the multipeptide formulation. Examples of pharmaceutically acceptable counter ions include acetate, HC1, and citrate. <br><br> A therapeutic composition for use in the invention should be sterile, stable under conditions of manufacture, storage, distribution and use and should be preserved 15 against the contaminating action of microorganisms such as bacteria and fungi. A <br><br> preferred means for manufacturing a therapeutic compositions of the invention in order to maintain the integrity of the composition (i.e. prevent contamination, prolong storage, etc.) is to prepare the formulation of peptide and pharmaceutically acceptable carrier(s) such that the composition may be in the form of a lyophilized powder which 20 is reconstituted in a pharmaceutically acceptable carrier, such as sterile water, just prior to use. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying, freeze-drying or spin drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. <br><br> 25 A preferred multipeptide formulation comprises the following unique peptides <br><br> DPI-21.2 (SEQ. ED. NO. 27), DH-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-22.14 (SEQ. ED. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) and sodium phosphate and mannitol, and optionally may further comprise DPII-20.9 (SEQ. ED. NO. 31). For this embodiment, EDTA is added to the 30 formulation. A suitable counter ion such as acetate may also be added during the preparation of the formulation. The formulation is preferably prepared in the form of a lyophilized powder which is reconstituted in a physiologically acceptable carrier, such as sterile water, prior to use. Several non-limiting examples of a preferred multipeptide formulations of this invention are described below. The unique house 35 dust mite protein allergen peptides will preferably be combined during manufacturing with the appropriate counter ion to produce one vial containing a sterile, pyrogen free, and preferably lyophilized powder of the desired formulation: <br><br> INTELLECTUAL PROPERTY OFFICE OF N.Z. <br><br> 2 &lt;i DEC 20M RECEIVED <br><br> 10 <br><br> Active: Der p I, Der/I and Der p II peptides DPI-21.2 (SEQ. ID. NO. <br><br> 27), DH-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. * 29), DPI-26.6 (SEQ. ED. NO. 30), DPII-22.14 (SEQ. ID. NO. 32) and DPH-25.15 (SEQ. ID. NO. 33) <br><br> In concentration of 0.75 mg per peptide Inactives: 0.05 M Sodium Phosphate U.S.P. <br><br> 5% w/v Mannitol, U.S.P. <br><br> 0.1 mg/ml EDTA disodium dihydrate U.S.P. <br><br> Final pH 7.2 -7.4 Diluent: Sterile Water for Injection, U.S.P. <br><br> 15 <br><br> 20 <br><br> 25 <br><br> Optionally active ingredients. <br><br> 0.75 mg of DPII-20.9 (SEQ. ID. NO. 31) may be added to the <br><br> A preferred combination of multipeptide formulations suitable for administration simultaneously or sequentially as a single treatment episode and contained in two separate sterile, pyrogen free vials preferably in the form of lyophilized powders include the following formulations: <br><br> Vial #1 <br><br> Active: Der p I, Derf I and Der p II peptides DH-22.2(SEQ. ED. NO. <br><br> 28), DPI-23.31 (SEQ. ID. NO. 29), and DPII-22.14 (SEQ. ID. <br><br> NO. 32) <br><br> In concentration of 0.75 mg per peptide Inactives: 0.05 M Sodium Phosphate U.S.P. <br><br> 5% w/v Mannitol, U.S.P. <br><br> 0.1 mg/ml EDTA disodium dihydrate <br><br> Final pH 7.0 Diluent: Sterile Water for Injection, U.S.P. <br><br> JO <br><br> Vial #2 <br><br> Active: Derp I, and Derp II peptides DPI-21.2 (SEQ. ID. NO. 27), <br><br> DPI-26.6 (SEQ. ID. NO. 30), DPII 20.9 (SEQ. ID. NO. 31), DPII-25.J5 (SEQ. ID. NO. <br><br> 33) <br><br> 5 In concentration of 0.75 mg per peptide <br><br> Inactives: 0.05 M Sodium Phosphate U.S.P. <br><br> 5% w/v Mannitol, U.S.P. <br><br> 0.1 mg/ml EDTA disodium dihydrate U.S.P. <br><br> Final pH 6.2 <br><br> 10 Diluent: Sterile Water for Injection, U.S.P. <br><br> The multipeptide formulations of the invention may also be provided in the form of a kit, including instructions for use. <br><br> Administration of the therapeutic compositions and multipeptide formulations 15. described above to an individual, preferably in non-immunogenic form, can be carried out using known procedures at dosages and for periods of time effective to cause down regulation of the house dust mite-specific immune response (i.e., reduce the allergic symptoms caused by house dust mite protein allergen of the individual. Down regulation of the allergic immune response to house dust mite allergen in humans may 20 be determined clinically whenever possible (see e.g., Varney et al, British Medical Journal, 302:265-269 (1990), or may be determined subjectively (i.e. the patient feels as if some or all of the allergic symptoms caused by house dust mite allergens have been alleviated). <br><br> One of the unique characteristics of each unique peptide in accordance with the 25 invention is that each peptide possesses "superior solubility". Therefore, compositions and multipeptide formulations of the invention are particularly suitable for administration by injection (e.g. subcutaneous, or intravenous). However, optimized compositions and multipeptide formulations of the invention may be administered in any convenient manner wherein solubility of the active drug component is either 30 desirable or acceptable, such as by injection (subcutaneous, intravenous, etc.), oral administration, sublingual, inhalation, transdermal application, rectal administration, or any other route of administration known in the art for administering soluble therapeutic agents. It may be desirable to administer simultaneously or sequentially a therapeutically effective amount of one or more of the therapeutic compositions used in the 35 invention to an individual as a single treatment episode. Each of such compositions for administration simultaneously or sequentially as a single treatment episode, may <br><br> */ <br><br> INTELLECTUAL PROPERTY OFFICE OF N.Z. <br><br> 2 4 DEC'2004 <br><br> comprise only one unique peptide of the invention or may comprise an optimized multipeptide formulation in accordance with the invention. <br><br> For subcutaneous injection of one or more therapeutic compositions and multipeptide formulations preferably about 1 jig- 3 mg and more <br><br> 5 preferably from about 20|ig-1.5 mg, and even more preferably about 50 \ig- 750 jig of each active component (peptide) per dosage unit may be administered. It is especially advantageous to formulate parenteral compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suited as unitary dosages for human subjects to be treated; 10 each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the desired pharmaceutical carrier. The specification for the novel unit dosage forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the <br><br> -t <br><br> 15 art of compounding such an active compound for the treatment of human subjects. <br><br> To administer a composition used in the invention by other than parenteral administration, (i.e. by oral administration) it may be necessary to coat the composition with, or co-administer the composition with, a material to prevent its inactivation or enhance its absorption and bioavailability. For example, a peptide formulation may be 20 co-administered with enzyme inhibitors or in liposomes. Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol. <br><br> Liposomes include water-in-oil-in-water CGF emulsions as well as conventional liposomes (Strejan et al., (1984) J. Neuroimmunol.. 7:27). When a peptide is suitably protected,, the peptide may be orally administered, for example, with an inert diluent or 25 an assimilable edible carrier. The peptide and other ingredients may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the individual's diet. For oral therapeutic administration, the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, solutions, gels, suspensions, syrups, wafers, and the 30 like. Such compositions and preparations should contain at least 1% by weight of active compound. The percentage of the composition and preparations may, of course, be varied and may conveniently be between about 5 to 80% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. In addition, the active compound may be 35 incorporated into sustained-release or controlled release (steady state or pulsatile . release) preparations and formulations. <br><br> 02 <br><br> INTELUECTUtt PROPERTY OFFICE (FttZ: <br><br> 2 4 0EC 20M RECEIVED <br><br> Effective amounts of the optimized drug compositions useful in the invention will vary according to factors such as the degree of sensitivity of the individual to the antigen, the age, sex, and weight of the individual, and the ability of peptide to cause down regulation of the antigen specific immune response in the individual. Dosage 5 regimen may be adjusted to provide the optimum therapeutic response. For example, <br><br> several divided doses may be administered over the course of days, weeks, months or years, or the dose may be proportionally increased or reduced with each subsequent injection as indicated by the exigencies of the therapeutic situation. In one preferred therapeutic regimen, subcutaneous injections of therapeutic compositions are given 10 once a week for 3-6 weeks. The dosage may remain constant for each injection or may increase or decrease with each subsequent injection. A booster injection may be administered at intervals of about three months to about one year after initial treatment and may involve only a single injection or may involve another series of injections similar to that of the initial treatment. &lt; <br><br> 15 This invention is illustrated by the following non-limiting examples. <br><br> Example 1 <br><br> Determination of the percentage of total house dust mite Group IT cell reactivity and patient coverage of the combination of unique Der p I and Derf I peptides. <br><br> 20 <br><br> Synthesis of Overlapping Peptides <br><br> Der p I was divided into a set of 17 overlapping peptides. Overlapping peptides and Der p I and Der f I unique peptides (i.e. DPI-21.2 (SEQ. ED. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30)) were 25 synthesized using standard Fmoc/tBoc synthetic chemistry and purified by Reverse Phase HPLC. Figure 1 shows the unique Der p I, and Derf I peptides and Figure 2 shows the overlapping Der p I peptides used in these studies. The peptide names are consistent throughout. <br><br> 30 T cell responses to Group I overlapping peptides and unique peptides <br><br> Peripheral blood mononuclear cells (PBMC) were purified by Ficoll-Hypaque centrifugation of 60 ml of heparinized peripheral blood from house dust mite-allergic individuals who exhibited clinical symptoms of mite allergy and who were skin test positive for house dust mite. <br><br> 35 10? PBMC from each patient were cultured in 5 ml RPMI-1640 <br><br> containing 5% pooled human AB serum and supplemented with glutamine, <br><br> penicillin, streptomycin and HEPES buffer in the presence of 20 (ag/ml purified in itLLECJUAL PROPERTY OFFICeI OF.Ni. . <br><br> 2 4 DEC 2004 -RECEIVED <br><br> native Der p I/ml at 37°C for 6 days. Viable cells were then purified by Ficoll-Hypaque centrifugation and cultured for 2-3 additional weeks in RPMI-1640/5% AB serum containing 5 units recombinant human IL-2/ml and 5 units recombinant human IL-4/ml. The resting T cells were then tested in a 5 secondary proliferation assay to assess T cell responses to purified native Der p I, overlapping peptides and unique peptides. For assay, 2 X 10^ resting T cells were cultured in 200 (il of RPMI-1640/5% AB serum for 3 days at 37°C in the presence of 2 X 10^ autologous Epstein-Barr virus transformed B cells (20,000 Rads) or in the presence of 5 X 10^ PBMC (3500 Rads) as antigen presenting 10 cells with various concentrations of purified native Der pi or synthetic Der p I unique peptide or overlapping peptides. Each well then received 1 fiCi tritiated thymidine for 16 hours. The counts incorporated were collected onto glass fiber filters and processed for liquid scintillation counting. Medium alone, <br><br> acting as negative control, contained no allergen or peptide. The results are 15 shown in Fig. 3. The highest stimulation index greater than or equal to 2.0 in response to each peptide was recorded for each subject tested. The data were then analyzed by the equations described earlier in the specification. <br><br> The combination of Group I candidate peptides DPI-21.2 (SEQ. ID. NO. 27), DH-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ED. NO. 29) DPI-26.6 20 (SEQ. ID. NO. 30), had a range of T cell reactivity of about 38-67% based on an analysis of 39 patients, the frequency of response at 82% represents reactivity to at least one of the candidate peptides, indicating that this combination of peptides fits the first criteria for "unique" peptides of the invention in that the combination of peptides DPI-21.2 (SEQ. ED. NO. 27), 25 DH-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. <br><br> ED. NO. 30), comprise a sufficient percentage of the total T cell reactivity to Group I protein allergens from Der p and Der f in a substantial percentage of the population tested. <br><br> 30 <br><br> Example 2 <br><br> Determination of the percentage of total house dust mite Group IIT cell reactivity and patient coverage of the combination of unique Derp I candidate peptides <br><br> 35 Synthesis of Overlapping Peptides <br><br> Der p II was divided into a set of 9 overlapping peptides. Overlapping Der p II peptides and Derpll unique peptides (i.e. DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 <br><br> jy <br><br> (SEQ. ED. NO. 32), and DPII-25.15 (SEQ. ID. NO. 33)) were synthesized using standard Fmoc/tBoc synthetic chemistry and purified by Reverse Phase HPLC. Figure 1 shows the unique Der p II peptides and Figure 2 shows the overlapping Der p II peptides used in these studies. The peptide names are consistent throughout. <br><br> 5 <br><br> T cell responses to Group II overlapping peptides and unique candidate peptides Secondary Der p II reactive T cell cultures derived from 30 mite-allergic patients were analyzed for reactivity to an overlapping set of Der p II peptides and Der p II candidate peptides, in an in vitro T cell proliferation assay as described in Example 10 1. The results are shown in Fig. 4. The highest stimulation index greater than or equal to 2.0 in response to each peptide was recorded for each subject tested. The data were then analyzed by the equations described earlier in the specification. <br><br> The combination of candidate peptides DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32), and DPII-25.15 (SEQ. ID. NO. 33), had a range of T cell 15 reactivity of about 36%-51% based on an analysis of 30 patients (Fig. 4). The frequency of response to at least one of the candidate peptides was about 63%, indicating that this combination of peptides fits the first criteria for "unique" peptides of the invention, in that the combination of Der p II peptides DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ED. NO. 32), and DPII-25.15 (SEQ. ID. NO. 33), comprise a 20 sufficient percentage of the total T cell reactivity to Der p II in a substantial percentage of the population tested. <br><br> Example-3 <br><br> Determination of pH-solubility and pH-stability profiles of candidate peptides of 25 the invention <br><br> 1. Buffer Preparation <br><br> 50 mM sodium phosphate stock solutions: <br><br> Stock solution A: 0.66 g (0.05 mol) of monobasic sodium phosphate 30 monohydrate U.S.P. and 50 mg EDTA disodium dihydrate, U.S.P. were dissolved in 100 mL of WFI. The solution was filtered through a 0.2 micron filter <br><br> Stock solution B: 0.71 g (0.05 mol) of dibasic sodium phosphate U.S.P. were disolved in 100ml WFI. The solution was filtered through a 0.2 micron filter. <br><br> 35 2. Initial peptide dispersions <br><br> Dispersion A: 3.0 mg of each candidate peptide,DPI-21.2 (SEQ. ED. NO. 27), DH-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. <br><br> 10 <br><br> 30), DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ED. NO. 32) and DPII-25.15 (SEQ. ED. NO. 33), was weighed out separately and placed in separate 1.5 mL eppendoff vials with 600 \iL of stock solution A. The composition was agitated for 5 seconds to mix well. <br><br> Dispersion B: 3.0 mg of each peptide, DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33), was weighed out separately and placed in separate 1.5 mL eppendoff vials with 600 |xL of stock solution B. The mixture was agitated for 5 seconds to mix well. <br><br> Dispersions A and B were sonicated for 2 minutes for good homogeneity. A small volume was pipetted from each dispersion into a labeled eppendoff vial according to the following volume ratio: <br><br> Vial# <br><br> Suspension A <br><br> Suspension B <br><br> Total Volume <br><br> Estimated final <br><br> (ML) <br><br> (ML) <br><br> (ML) <br><br> PH <br><br> 1 <br><br> 100 <br><br> 0 <br><br> 100 <br><br> 5.2 ; <br><br> 2 <br><br> 80 <br><br> 20 <br><br> 100 <br><br> 6.2 <br><br> 3 <br><br> 60 <br><br> 40 <br><br> 100 <br><br> 6.6 <br><br> 4 <br><br> 40 <br><br> 60 <br><br> 100 <br><br> 6.8 <br><br> 5 <br><br> 20 <br><br> 80 <br><br> 100 <br><br> 7.1 <br><br> 6 <br><br> 0 <br><br> 100 <br><br> 100 <br><br> 8.0 <br><br> 15 The resultant solutions/suspensions were stored in the dark at about 22°C + 2 for 24 hours without agitation. The solutions were filtered and filtrates were analyzed for pH and peptide concentration. <br><br> The1 concentration of filtered peptide solutions was determined by HPLC analysis. In this experiment, the solubility of peptide at each pH is defined as the 20 amount of peptide remaining in solution after filtration through a membrane filter having a 0.2 micrometer pore size. The extent of degradation of peptides was estimated by calculating the percent of total degradant peak area over the total peak area. <br><br> The pH values with respect to the solubility values was plotted and are shown 25 in Fig. 5 for each respective peptide. As shown in the solubility curve for each peptide as represented in Fig. 5, peptides DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) are each soluble at greater than 3 mg/ml at a pH in the pH range of pH 6 to pH 8. 30 The pH-stability profiles for each peptide DPI-21.2 (SEQ. ID. NO. 27), DFI- <br><br> 22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), <br><br> 26 <br><br> 502480 <br><br> DPH-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) in equal concentration combination at 3, 2, and 1 mg/ml per peptide and prepared in duplicate as described above with one set stored at about 5° C for 24 hours and one set stored at about 22°C ± 2 for 24 hours, were calculated and tabulated as a 5 function of the percentage of total of degradant peak area (Fig. 6). As can be seen from the data in Fig. 6, the percent degradation of peptide at each concentration was less for peptides stored at about 5°C for 24 hours as compared to peptides stored at 22° C + 2 for 24 hours over the critical pH range of pH 6.0 to pH 8.0. However, <br><br> acceptable solution stability is demonstrated for all the peptides in a common 10 "window" within the pH range of pH 6 to pH 8 at either temperature. <br><br> Therefore, each of peptides DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) was determined to possess the appropriate solubility and stability required of a unique 15 peptide of the invention. <br><br> Although the invention has been described with reference to its preferred embodiments, other embodiments, can achieve the same results. Variations and modifications to the present invention will be obvious to those skilled in the art and it is intended to cover in the appended claims all such modification and equivalents and 20 follow in the true spirit and scope of this invention. <br><br> J? 7 <br><br> 5 <br><br> 10 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 35 <br><br> 40 <br><br> 45 <br><br> 50 <br><br> 55 <br><br> 60 <br><br> SEQUENCE LISTING <br><br> (1) GENERAL INFORMATION: <br><br> (1) GENERAL INFORMATION: <br><br> (i) APPLICANT: <br><br> (A) NAME: IMMULOGIC PHARMACEUTICAL CORPORATION <br><br> (B) STREET: 610 Lincoln Street <br><br> (C) CITY: Waltham <br><br> (D) STATE: MA <br><br> (E) COUNTRY: USA <br><br> (F) POSTAL CODE (ZIP) : 02154 <br><br> (G) TELEPHONE: (617) 466-6000 <br><br> (H) TELEFAX: (617)4 66-604 0 <br><br> (ii) TITLE OF INVENTION: PHARMACEUTICAL PEPTIDE FORMULATIONS FOR TREATMENT OF DUST MITE ALLERGY <br><br> (iii) NUMBER OF SEQUENCES: 54 ; <br><br> (iv) COMPUTER READABLE FORM: <br><br> (A) MEDIUM TYPE: Floppy disk <br><br> (B) COMPUTER: IBM PC compatible <br><br> (C) OPERATING SYSTEM: PC-DOS/MS-DOS <br><br> (D) SOFTWARE: Patentln Release #1.0, Version #1.30 (EPO) <br><br> (vi) PRIOR APPLICATION DATA: <br><br> (A) APPLICATION NUMBER: 08/227,772 <br><br> (B) FILING DATE: April 14, 1994 <br><br> (viii) ATTORNEY/AGENT INFORMATION: <br><br> (A) NAME: Vanstone, Darlene A. <br><br> (B) REGISTRATION NUMBER: 35,279 <br><br> (C) REFERENCE/DOCKET NUMBER: 017.5 PCT <br><br> (ix).TELECOMMUNICATION INFORMATION: <br><br> (A) TELEPHONE: (617) 466-6000 <br><br> (B) TELEFAX: (617) 466-6010 <br><br> (2) INFORMATION FOR SEQ ID NO: 1: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 20 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: <br><br> Thr Asn Ala Cys Ser lie Asn Gly Asn Ala Pro Ala Glu lie Asp 15 10 15 <br><br> At <br><br> 5 <br><br> 10 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 35 <br><br> 40 <br><br> 45 <br><br> 50 <br><br> 55 <br><br> 60 <br><br> 65 <br><br> Leu Arg Gin Met Arg 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 2: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 27 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: <br><br> Glu lie Asp Leu Arg Gin Met Arg Thr Val Thr Pro lie Arg Met Gin 1 5 10 15 <br><br> Gly Gly Cys Gly Ser Cys Trp Ala Phe Ser Gly <br><br> 20 25 * <br><br> (2) INFORMATION FOR SEQ ID NO: 3: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 29 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: <br><br> Thr Val Thr Pro lie Arg Met Gin Gly Gly Cys Gly Ser Cys Trp Ala 15 10 15 <br><br> Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr Leu Ala 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 4: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 21 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) <br><br> Val <br><br> SEQUENCE DESCRIPTION: SEQ ID NO: 4: <br><br> Ala Ala Thr Glu Ser Ala Tyr Leu Ala His Arg Asn Gin Ser Leu <br><br> 5 <br><br> 10 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 35 <br><br> 40 <br><br> 45 <br><br> 50 <br><br> 55 <br><br> 60 <br><br> 65 <br><br> l <br><br> 5 <br><br> 10 <br><br> 15 <br><br> Asp Leu Ala Glu Gin <br><br> 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 5: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 22 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: <br><br> His Arg Asn Gin Ser Val Asp Leu Ala Glu Gin Glu Leu Val Asp Cys 15 10 15 <br><br> Ala Ser Gin His Gly Cys * <br><br> 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 6: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 21 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: <br><br> Glu Leu Val Asp Cys Ala Ser Gin His Gly Cys His Gly Asp Thr lie 15 10 15 <br><br> Pro Arg Gly lie Glu 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 7: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 20 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: <br><br> So <br><br> 5 <br><br> 10 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 35 <br><br> 40 <br><br> 45 <br><br> 50 <br><br> 55 <br><br> 60 <br><br> 65 <br><br> Glu Tyr lie Gin His Asn Gly Val Val Gin Glu Ser Tyr Tyr Arg Tyr 15 10 15 <br><br> Val Ala Arg Glu 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 8: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 25 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: <br><br> His Asn Gly Val Val Gin Glu Ser Tyr Tyr Arg Tyr Val Ala Arg Glu 15 10 15 <br><br> Gin Ser Cys Arg Arg Pro Asn Ala Gin 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 9: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 19 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNES S: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: <br><br> Gin Ser Cys Arg Arg Pro Asn Ala Gin Arg Phe Gly He Ser Asn Tyr 15 10 15 <br><br> Cys Gin lie <br><br> (2) INFORMATION FOR SEQ ID NO: 10: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 22 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: <br><br> 3/ <br><br> 5 <br><br> 10 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 35 <br><br> 40 <br><br> 45 <br><br> 50 <br><br> 55 <br><br> 60 <br><br> 65 <br><br> Arg Phe Gly lie Ser Asn Tyr Cys Gin lie Tyr Pro Pro Asn Ala Asn 15 10 15 <br><br> Lys lie Arg Glu Ala Leu 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 11: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 24 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: <br><br> Tyr Pro Pro Asn Ala Asn Lys lie Arg Glu Ala Leu Ala Gin Thr His 15 10 15 - <br><br> Ser Ala lie Ala Val lie lie Gly 20 <br><br> (2) INFORMATION FOR SEQ ID NO: .12: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 2 6 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: <br><br> Ala Gin Thr His Ser Ala lie Ala Val lie lie Gly lie Lys Asp Leu 15 10 15 <br><br> Asp Ala Phe Arg His Tyr Asp Gly Arg Thr 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 13: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 2 6 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide <br><br> (v) FRAGMENT TYPE: internal <br><br> 3A <br><br> 5 <br><br> 10 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 35 <br><br> 40 <br><br> 45 <br><br> 50 <br><br> 55 <br><br> 60 <br><br> 65 <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: <br><br> lie Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr lie lie 15 10 15 <br><br> Gin Arg Asp Asn Gly Tyr Gin Pro Asn Tyr 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 14: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 23 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: <br><br> lie lie Gin Arg Asp Asn Gly Tyr Gin Pro Asn Tyr His Ala Val' Asn 15 10 15 <br><br> lie Val Gly Tyr Ser Asn Ala 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 15: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 22 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: <br><br> His Ala Val Asn lie Val Gly Tyr Ser Asn Ala Gin Gly Val Asp Tyr 15 10 15 <br><br> Trp lie Val Arg Asn Ser 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 16: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 24 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide <br><br> (v) FRAGMENT TYPE: internal <br><br> 33 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 35 <br><br> 40 <br><br> 45 <br><br> 50 <br><br> 55 <br><br> 60 <br><br> 65 <br><br> (xi) SEQUENCE DESCRIPTION: SEQ -ID NO: 16: <br><br> Gin Gly Val Asp Tyr Trp lie Val Arg Asn Ser Trp Asp Thr Asn Trp 1 5 10 15 <br><br> Gly Asp Asn Gly Tyr Gly Tyr Phe 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 17: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 26 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: <br><br> Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn lie Asp Leu Met ^let 1 5 10 15 ' <br><br> lie Glu Glu Tyr Pro Tyr Val Val lie Leu 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 18: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 20 amino acids <br><br> (B) TYPE: amino acid '(C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (V) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: <br><br> Asp Gin Val Asp Val Lys Asp Cys Ala Asn His Glu lie Lys Lys Val 15 10 15 <br><br> Leu Val Pro Gly 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 19: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 25 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide <br><br> (v) FRAGMENT TYPE: internal <br><br> 3V <br><br> 5 <br><br> 10 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 35 <br><br> 40 <br><br> 45 <br><br> 50 <br><br> 55 <br><br> 60 <br><br> 65 <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: <br><br> His Glu lie Lys Lys Val Leu Val Pro Gly Cys His Gly Ser Glu Pro 15 10 15 <br><br> Cys lie lie His Arg Gly Lys Pro Phe 20 25 <br><br> INFORMATION FOR SEQ ID NO: 20: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 29 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: ; <br><br> His Gly Ser Glu Pro Cys lie lie His Arg Gly Lys Pro Phe Gin Leu 1 5 10 15 <br><br> Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys Thr. Ala 20 25 <br><br> INFORMATION FOR SEQ ID NO: 21: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 25 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii.)' MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21: <br><br> Gin Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys Thr Ala Lys 15 10 15 <br><br> lie Glu lie Lys Ala Ser lie Asp Gly 20 25 <br><br> INFORMATION FOR SEQ ID NO: 22: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 27 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide <br><br> 5 <br><br> 10 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 35 <br><br> 40 <br><br> 45 <br><br> 50 <br><br> 55 <br><br> 60 <br><br> 65 <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: <br><br> Lys lie Glu lie Lys Ala Ser lie Asp Gly Leu Glu Val Asp Val Pro 15 10 15 <br><br> Gly lie Asp Pro Asn Ala Cys His Tyr Met Lys 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 23: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 2 6 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23: <br><br> Leu Glu Val Asp Val Pro Gly lie Asp Pro Asn Ala Cys His Tyr Met 15 10 15 <br><br> Lys Cys Pro Leu Val Lys Gly Gin Gin Tyr 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 24: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 27 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v.) .'FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24: <br><br> Cys Pro Leu Val Lys Gly Gin Gin Tyr Asp lie Lys Tyr Thr Trp Asn 15 10 15 <br><br> Val Pro Lys lie Ala Pro Lys Ser Glu Asn Val 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 25: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 26 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide <br><br> (v) FRAGMENT TYPE: internal <br><br> 36 <br><br> 5 <br><br> 10 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 35 <br><br> 40 <br><br> 45 <br><br> 50 <br><br> 55 <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25: <br><br> Asp lie Lys Tyr Thr Trp Asn Val Pro Lys lie Ala Pro Lys Ser Glu 15 10 15 <br><br> Asn Val Val Val Thr Val Lys Val Met Gly 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 26: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 25 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNES S: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: ' <br><br> Val Val Thr Val Lys Val Met Gly Asp Asp Gly Val Leu Ala Cys Ala 15 10 15 <br><br> lie Ala Thr His Ala Lys lie Arg Asp 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 27: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 24 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNES S: <br><br> (D) TOPOLOGY: linear <br><br> - (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27: <br><br> Ser lie Asn Gly Asn Ala Pro Ala Glu lie Asp Leu Arg Gin Met Arg 15 10 15 <br><br> Thr Val Thr Pro lie Arg Met Gin 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 28: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 25 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide <br><br> (v) FRAGMENT TYPE: internal <br><br> 37 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 35 <br><br> 40 <br><br> 45 <br><br> 50 <br><br> 55 <br><br> 60 <br><br> 65 <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28: <br><br> Val Ala Ala Thr Glu Ser Ala Tyr Leu Ala Tyr Arg Asn Thr Ser Leu 15 10 15 <br><br> Asp Leu Ser Glu Gin Glu Leu Val Asp 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 29: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 26 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29: <br><br> Asp Glu Glu Gly Val Val Gin Glu Ser Tyr Tyr Arg Tyr Val Ala Arg 15 10 15 <br><br> Glu Gin Ser Cys Arg Arg Pro Asn Ala Glu 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 30: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 2 6 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii)- MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: <br><br> Asp Glu Gly lie Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg 15 10 15 <br><br> Thr lie lie Gin Arg Asp Asn Gly Tyr Glu 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 31: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 25 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide <br><br> 3^ <br><br> 5 <br><br> 10 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 35 <br><br> 40 <br><br> 45 <br><br> 50 <br><br> 55 <br><br> 60 <br><br> 65 <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: <br><br> Asp Gin Val Asp Val Lys Asp Cys Ala Asn His Glu lie Lys Lys Val 15 10 15 <br><br> Leu Val Pro Gly Cys His Gly Ser Glu 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 32: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 2 0 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32: <br><br> Asp Lys Glu Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys". Thr 15 10 15 <br><br> Ala Lys Ala Glu 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 33: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 2 8 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v)" FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33: <br><br> Asp Glu Glu Thr Val Lys Val Met Gly Asp Asp Gly Val Leu Ala Cys 15 10 15 <br><br> Ala lie Ala Thr His Ala Lys lie Arg Asp Glu Glu 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 34: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 2 8 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide <br><br> (v) FRAGMENT TYPE: internal <br><br> J? <br><br> 5 <br><br> 10 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 35 <br><br> 40 <br><br> 45 <br><br> 50 <br><br> 55 <br><br> 60 <br><br> 65 <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34: <br><br> Gin Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys Thr Ala Lys 1 5 10 15 <br><br> lie Glu lie Lys Ala Ser lie Asp Gly Leu Glu Val 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 35: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 30 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35: <br><br> Lys Gin Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys Thr Ala 1 5 10 .15 <br><br> Lys lie Glu lie Lys Ala Ser lie Asp Gly Leu Glu Val Lys 20 25 30 <br><br> (2) INFORMATION FOR SEQ ID NO: 36: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 31 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) ."'FRAGMENT TYPE: internal <br><br> (Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36: <br><br> Asp Lys Gin Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys Thr 15 10 15 <br><br> Ala Lys lie Glu lie Lys Ala Ser lie Asp Gly Leu Glu Val Asp 20 25 30 <br><br> (2) INFORMATION FOR SEQ ID NO: 37: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 25 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide <br><br> (v) FRAGMENT TYPE: internal <br><br> HO <br><br> 5 <br><br> 10 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 35 <br><br> 40 <br><br> 45 <br><br> 50 <br><br> 55 <br><br> 60 <br><br> 65 <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37: <br><br> Gin Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys Thr Ala Lys 15 10 15 <br><br> lie Glu lie Lys Ala Ser lie Asp Glu 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 38: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 27 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38: : <br><br> Asp Lys Gin Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys Thr 15 10 15 <br><br> Ala Lys lie Glu lie Lys Ala Ser lie Asp Glu 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 39: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 28 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii),'MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39: <br><br> Asp Lys Glu Gin Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys 15 10 15 <br><br> Thr Ala Lys lie Glu lie Lys Ala Ser lie Asp Glu 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 40: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 29 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide <br><br> (v) FRAGMENT TYPE: internal y/ <br><br> 5 <br><br> 10 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 35 <br><br> 40 <br><br> 45 <br><br> 50 <br><br> 55 <br><br> 60 <br><br> 65 <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40: <br><br> Asp Lys Glu Gin Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys 15 10 15 <br><br> Thr Ala Lys lie Glu lie Lys Ala Ser lie Asp Glu Glu 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 41: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 27 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41: <br><br> Asp Lys Gin Leu Glu Ala Val Phe Glu Ala Asn Gin Ala Thr Lys Thr 15 10 15 <br><br> Ala Lys lie Glu lie Lys Ala Ser lie Asp Glu 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 42: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 25 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) ''MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42: <br><br> Asp Glu Lys Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys Thr 15 10 15 <br><br> Ala Lys lie Glu lie Lys Ala Ser Asp 20 25 <br><br> (2) INFORMATION FOR SEQ ID NO: 43: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 24 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide <br><br> (v) FRAGMENT TYPE: internal <br><br> &amp; <br><br> 5 <br><br> 10 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 35 <br><br> 40 <br><br> 45 <br><br> 50 <br><br> 55 <br><br> 60 <br><br> 65 <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43: <br><br> Asp Lys Glu Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys Thr 15 10 15 <br><br> Ala Lys lie Glu lie Lys Ala Asp 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 44: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 24 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNES S: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44: <br><br> Asp Lys Glu Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys Thr 15 10 15 <br><br> Ala Lys lie Glu lie Lys Ala Lys 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 45: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 23 amino acids <br><br> (B) TYPE: amino acid • (C) STRANDEDNESS: <br><br> ' (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45: <br><br> Asp Lys Glu Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys Thr 1 5 10 15 <br><br> Ala Lys lie Glu lie Lys Asp 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 46: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 23 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide <br><br> ¥3 <br><br> 5 <br><br> 10 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 35 <br><br> 40 <br><br> 45 <br><br> 50 <br><br> 55 <br><br> 60 <br><br> 65 <br><br> (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46: <br><br> Asp Lys Glu Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys Thr 15 10 15 <br><br> Ala Lys lie Glu lie Lys Lys 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 47: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 22 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47: <br><br> Asp Lys Glu Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys Thr 15 10 15 <br><br> Ala Lys lie Glu lie Lys 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 48: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 21 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> 5 (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48: <br><br> Asp Lys Glu Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys Thr 15 10 15 <br><br> Ala Lys lie Glu Asp 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 49: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 21 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide <br><br> 15 <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 35 <br><br> 40 <br><br> 45 <br><br> 50 <br><br> 55 <br><br> 60 <br><br> 65 <br><br> (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49: <br><br> Asp Lys Glu Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys Thr 15 10 15 <br><br> Ala Lys lie Glu Lys 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 50: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 2 0 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50: <br><br> Asp Lys Glu Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys Thr 1 5 10 15 <br><br> Ala Lys lie Glu 20 <br><br> (2) INFORMATION FOR SEQ ID NO: 51: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> IA) LENGTH: 15 amino acids . (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> "(D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide <br><br> (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51: <br><br> Leu Glu Ala Val Phe Glu Ala Asn Gin Asn Thr Lys Thr Ala Lys 15 10 15 <br><br> (2) INFORMATION FOR SEQ ID NO: 52: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 15 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide <br><br> (v) FRAGMENT TYPE: internal <br><br> 5 <br><br> 10 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> 30 <br><br> 35 <br><br> 40 <br><br> 45 <br><br> 50 <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52: <br><br> Leu Glu Ala Val Phe Glu Ala Asn Gin Ala Thr Lys Thr Ala Lys 1 5 10 15 <br><br> (2) INFORMATION FOR SEQ ID NO: 53: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 16 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNESS: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53: <br><br> Asp Lys Thr Ala Lys lie Glu lie Lys Ala Ser lie Asp Gly Leu' Glu 15 10 15 <br><br> (2) INFORMATION FOR SEQ ID NO: 54: <br><br> (i) SEQUENCE CHARACTERISTICS: <br><br> (A) LENGTH: 15 amino acids <br><br> (B) TYPE: amino acid <br><br> (C) STRANDEDNES S: <br><br> (D) TOPOLOGY: linear <br><br> (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal <br><br> (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54: <br><br> Lys Thr Ala Lys lie Glu lie Lys Ala Ser lie Asp Gly Leu Glu 15 10 15 <br><br></p> </div>

Claims (5)

  1. <div class="application article clearfix printTableText" id="claims"> <p lang="en"> What we claim is:<br><br> 1 An in vitro method of treating sensitivity to house dust mite allergen comprising administering simultaneously or sequentially at least two different compositions comprising at least one isolated peptide selected from the group consisting of: DPI-ll.2 (SEQ. ED. NO. 27) and DFI-22.2 (SEQ. ID.<br><br> 5 NO. 28), and at least one peptide selected from the group consisting of: DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPH-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) all as shown in Fig. 1.<br><br>
  2. 2. An in vitro method of treating sensitivity to house dust mite allergen comprising administering a therapeutic composition comprising peptides DPI-21.2 (SEQ. ID. NO. 27),<br><br> DH-22.2 (SEQ. ID. NO. 28), DPl-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ED. NO.<br><br> 30), DPII-22.14 (SEQ. ED. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33).<br><br>
  3. 3, An in vitro method of treating sensitivity to house dust mite allergen &lt;<br><br> comprising administering a therapeutic composition as defined in claim 2 and further comprising DPII-20.0 (SEQ.ID.NO.31).<br><br>
  4. 4. An in vitro method of treating sensitivity to house dust'mite allergy comprising administering an multipeptide formulation suitable for therapeutic treatment of humans suffering from allergy to house dust mite and optimized for stability, efficacy or dosage, said formulation comprising:<br><br> Peptides DPI-21.2 (SEQ. ID. NO. 27), DH-22.2 (SEQ. ID. NO. 28), DPI-2331-(SEQ. ID. NO. 29), DPI-26.6 (SEQ. ED. NO. 30), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ED. NO. 33), each peptide in a concentration of 0.75 mg per peptide; 0.05 M sodium phosphate U.S.P.;<br><br> 5 w/v Mannitol, U.S.P.;<br><br> 0.1 mg/ml EDTA disodium dihydrate U.S P.; and Sterile Water for injection U.S.P;<br><br> wherein said formulation has a final pH of 7.2-7.4.<br><br> 47<br><br> INTELLECTUAL PROPERTY OFFICE 0FN2.<br><br> 2 4 DEC 2004 RECEIVED<br><br>
  5. 5. An in vitro method of treating sensitivity to house dust mite allergy comprising administering simultaneously or sequentially, as a single treatment episode,<br><br> first and second multipeptide formulationaoptimized for stability, efficacy or dosage wherein said first formulation comprises:<br><br> peptides DH-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ED. NO. 29), and DPII-22.14 (SEQ. ED. NO. 32), each peptide in a concentration of 0.75 mg per peptide; 0.05 M sodium phosphate U.S.P.;<br><br> 5% w/v Mannitol, U.S.P.;<br><br> 0.1 mg/ml EDTA disodium dihydrateU.S.P.; and Sterile Water for injection U.S.P; having a final pH of 7.0;<br><br> and wherein said second optimized multipeptide formulation comprises:<br><br> Peptides DPI-21.2 (SEQ. ED. NO. 27), DPI-26.6 (SEQ. ID. NO. 30), and DPII-25.15 (SEQ. ED. NO. 33), each peptide in a concentration of 0.75 mg per peptide; 0.05 M sodium phosphate U.S.P.;<br><br> 5% w/v Mannitol, U.S.P.;<br><br> 0.1 mg/ml EDTA disodium dihydrate U.S.P.; and *-;Sterile Water for injection U.S.P; having a final pH of 6.2.;END OF CLAIMS;48;INTELLECTUAL PROPERTY OFFICE OF N.Z.;2 * DEC 2004 | ..RECEIVED<br><br> </p> </div>
NZ502480A 1994-04-14 1998-08-03 Pharmaceutical peptide formulations for treatment of dust mite allergy NZ502480A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/227,722 US5611601A (en) 1994-04-14 1994-04-14 Method and means for facilitating rest for a person in a sitting position

Publications (1)

Publication Number Publication Date
NZ502480A true NZ502480A (en) 2005-02-25

Family

ID=22854201

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ331232A NZ331232A (en) 1994-04-14 1995-04-12 Treating dust mite allergies using peptide formulations
NZ502480A NZ502480A (en) 1994-04-14 1998-08-03 Pharmaceutical peptide formulations for treatment of dust mite allergy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ331232A NZ331232A (en) 1994-04-14 1995-04-12 Treating dust mite allergies using peptide formulations

Country Status (2)

Country Link
US (1) US5611601A (en)
NZ (2) NZ331232A (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042185A (en) * 1994-04-14 2000-03-28 Brex, Inc. Method and means for facilitating rest for a person in a sitting position
US6820852B2 (en) * 2001-09-27 2004-11-23 Joyce E. Wainscott Pillow book holder and method therefor
US6647573B2 (en) * 2002-03-05 2003-11-18 David Allan Corbin Air travel pillow
GB2392835A (en) * 2002-09-12 2004-03-17 Andrew Allum Inflatable relaxation chair
US20040064893A1 (en) * 2002-10-04 2004-04-08 Richard Sharp Inflatable resting device
US6805403B2 (en) * 2002-12-26 2004-10-19 Pradip Chandrakant Buch Facilitate sleeping of a person in sitting position by supporting the head and/or body
US6973691B1 (en) * 2004-06-14 2005-12-13 Lora May Cordova Head, neck and upper body support pillow
GB0413674D0 (en) * 2004-06-18 2004-07-21 Maginness Joseph G Head support
US7866696B2 (en) * 2004-12-10 2011-01-11 GM Global Technology Operations LLC Vehicle seat assembly
GB0525629D0 (en) * 2005-12-16 2006-01-25 Maginness Joseph G A combination carrier unit and head support apparatus
US7475442B1 (en) * 2007-11-20 2009-01-13 Daniel Dierking Baby soothing apparatus
US7909406B2 (en) * 2008-11-12 2011-03-22 Samuelsen Leif-Erik A Resting apparatus
US20100180382A1 (en) * 2009-01-21 2010-07-22 Tracey Lee-Anne Hunter SkyRest Child+ travel pillow
US7788751B1 (en) * 2009-02-04 2010-09-07 Stephen K. Diemer Sitting neck support device
US8584283B2 (en) * 2010-05-17 2013-11-19 Robert Mabry Portable sleeping device
US8528970B2 (en) 2011-01-17 2013-09-10 Mohsen Edalati Multi-adjustable body-rest apparatus
AT12419U1 (en) * 2011-03-04 2012-05-15 Pusca Herwig SERENITY SUPPORT FACILITY
US8528978B2 (en) * 2011-11-02 2013-09-10 The Boeing Company Transport vehicle seat back with integrated upright sleep support system
US9635962B2 (en) 2012-04-12 2017-05-02 Cabeau, Inc. Travel pillow with lateral and rear support bar and a flat and thin back
US9968198B2 (en) * 2013-02-04 2018-05-15 Hauerdesigns Llc Contoured travel pillow
US9027185B2 (en) 2013-07-17 2015-05-12 Joseph L Garcia Portable head support device
CN104757808A (en) * 2015-04-23 2015-07-08 田洪斌 Instrument for sleeping on seat conveniently
US20180132621A1 (en) * 2015-06-09 2018-05-17 Hairy Turtle Pty Ltd Portable cushioned support
GB2601259B (en) * 2015-06-09 2022-11-02 Hairy Turtle Pty Ltd Portable cushioned support
USD808686S1 (en) 2016-12-14 2018-01-30 SnoozeWell, LLC Pillow
US9943179B1 (en) * 2016-12-14 2018-04-17 SnoozeWell, LLC Upright sleep system
US10232815B1 (en) * 2017-10-18 2019-03-19 Ford Global Technologies, Llc Seat assembly
CN111727024A (en) * 2018-02-16 2020-09-29 卡布公司 Head support device
USD898424S1 (en) * 2018-06-08 2020-10-13 Clay Martin Jackson Forward-supporting travel cushion
JP6482714B1 (en) * 2018-10-05 2019-03-13 祐二 ▲片▼江 CT examination sitting chair
US11628749B2 (en) 2020-02-26 2023-04-18 GM Global Technology Operations LLC Vehicle seat for a motor vehicle and method of positioning the same
USD923968S1 (en) 2020-06-26 2021-07-06 Clay Martin Jackson Child's forward-supporting cushion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US623548A (en) * 1899-04-25 The norris peters co
US2829386A (en) * 1954-03-22 1958-04-08 Daniel I Peer Combined life preserver and cushion
US3029109A (en) * 1957-07-26 1962-04-10 Walter P Nail Control of inflatable articles
US2987735A (en) * 1957-07-26 1961-06-13 Walter P Nail Control of inflatable articles
US3017642A (en) * 1959-11-27 1962-01-23 Holiday Line Inc Self-inflating cushion
US4025105A (en) * 1973-09-10 1977-05-24 Pekala Charles T Sports (back) seat
US4235472A (en) * 1978-06-22 1980-11-25 Robert Sparks Sleeping device for sitting position
US4232477A (en) * 1979-05-11 1980-11-11 Shelcore, Inc. Inflatable hassock-shaped toy
US4774735A (en) * 1987-09-14 1988-10-04 William Sanderson Folding cushion

Also Published As

Publication number Publication date
US5611601A (en) 1997-03-18
NZ331232A (en) 2000-02-28

Similar Documents

Publication Publication Date Title
NZ502480A (en) Pharmaceutical peptide formulations for treatment of dust mite allergy
US5820862A (en) T cell epitopes of the major allergens from dermatophagoides (house dust mite)
US7407657B2 (en) T-cell epitope peptides
JP4179422B2 (en) Pharmaceutical composition for treating cedar pollen allergy
KR100393508B1 (en) New hIL-4 Mutant Proteins as Antagonists or Partial Agonists of Human Interleukin 4
EP0537280B1 (en) Preparation and use of transfer factor
AU717187B2 (en) Pharmaceutical peptide formulations for treatment of dust mite allergy
Rogers et al. Recombinant Fel d I: Expression, purification, IgE binding and reaction with cat-allergic human T cells
US7288256B1 (en) T cell epitopes of the major allergens from dermatophagoides (house dust mite)
WO1998043657A9 (en) Graminae pollen allergen mutants for specific immunotherapy, and production and use of the same
RU2202364C2 (en) High activity muteins of interleukin-4
EP1009419A2 (en) Graminae pollen allergen mutants for specific immunotherapy, and production and use of the same
JPH09504167A (en) T cell epitopes of the wheat allergen
US5698204A (en) Recombinant allergenic proteins from ragweed pollen
JPH0847392A (en) Allergen cry j ii epitope of pollen of japanese cedar
KR20040004481A (en) Nucleic acids encoding a house dust mite allergen, der p iii, and uses therefor
CA2495825C (en) Variants of the major allergen phl p 1 from timothy grass
JPH09501043A (en) T cell epitopes of major allergens derived from DERMATOPHAGOIDES
KR100562821B1 (en) T Cell Epitope Peptide
JP2006045230A (en) T-cell epitope peptide

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: MERCK PATENT GMBH, DE

Free format text: OLD OWNER(S): HESKA CORPORATION

Owner name: MERCK PATENT GMBH, DE

Free format text: OLD OWNER(S): MERCK PATENT GMBH

RENW Renewal (renewal fees accepted)
EXPY Patent expired